



## Press release

### TxCell to participate in leading scientific conferences in Q3 2016

**Valbonne, France, July 11, 2016 – TxCell SA (FR0010127662 – TXCL)**, a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells (Treg) to treat severe chronic inflammatory and autoimmune diseases, announces today that some of TxCell's teams will present at and attend a number of leading scientific conferences during the third quarter of 2016.

These conferences include:

- **International Society for Cellular Therapy (ISCT) North America 2016 Regional Meeting**, September 30 - October 2, Memphis, United States
  - Miguel Forte, Chief Operating Officer of TxCell and Chief Commercialization Officer of the ISCT, will chair a special Commercialization Committee Signature Series day on September 29 (9am-6pm) that will cover a wide range of topics critical to the ongoing development of the cell therapy industry. These topics include product characterization, clinical development and market access. World leaders in the cellular therapy field will participate in this meeting, including Bruce Levine, Director, Clinical Cell and Vaccine Production at the University of Pennsylvania (Philadelphia), Qizhi Tang, Associate Professor at the UCSF School of Medicine (San Francisco) and Arnaud Foussat, Chief Scientific Officer of TxCell.
- **Phacilitate Leaders Forum** (including both **Cell & Gene Therapy Europe** and **Immunotherapy Europe**), September 21-22, Berlin, Germany
  - Miguel Forte will contribute to a panel discussion entitled 'Addressing remaining logistical bottlenecks in clinical and commercial European ATMP supply chains' on September 22 at 12.05pm local time.
  - Miguel Forte will also contribute to the closing panel discussion on September 22 at 3.40pm local time, which will address the impact of T cell and NK cell immunotherapies in the autoimmune area.
  - For more information on the Phacilitate Leaders Forum: [www.cgteurope.com](http://www.cgteurope.com).
- **International Congress of Immunology 2016 (ICI 2016)**, August 21-26, Melbourne, Australia
  - An oral presentation entitled 'High-content cytotoxic assays reveal the biological activity of pathological and therapeutical cytotoxic T lymphocytes' will be presented by Delphine Guipouy, a PhD student affiliated to TxCell's research department, on August 22 at 11.50am local time. This presentation will further explore the mechanism of action of TxCell's drug-candidates.
  - For more information on the ICI 2016 conference: [www.ici2016.org](http://www.ici2016.org).

## About TxCell – [www.txcell.com](http://www.txcell.com)

TxCell is a biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe chronic inflammatory and autoimmune diseases with high unmet medical need. TxCell is the only clinical stage cellular therapy company dedicated to the science of regulatory T lymphocytes (Tregs). Tregs are a recently discovered T cell population for which anti-inflammatory properties have been demonstrated.

TxCell is developing two proprietary technology platforms, ASTrIA and ENTrIA. ASTrIA is composed of autologous antigen-specific Type 1 Tregs. Ovasave®, TxCell's lead drug-candidate originating from the ASTrIA platform, is currently in a phase IIb clinical trial in refractory Crohn's disease patients. ENTrIA is composed of Chimeric Antigen Receptor engineered FoxP3+ regulatory T cells (CAR-Treg). TxCell launched two CAR-Treg development programs in Q2 2016, a first one targeting Lupus Nephritis with Ospedale San Raffaele (OSR) and a second one targeting Bullous Pemphigoid with the Lübeck Institute of Experimental Dermatology (LIED).

Based in Sophia-Antipolis, France, TxCell is listed on Euronext Paris and currently has 50 employees.

## Contacts

### **TxCell**

Caroline Courme  
IR & Communication Director  
Tel: +33(0) 4 97 21 83 00  
[caroline.courme@txcell.com](mailto:caroline.courme@txcell.com)

### **Image Box – Press relations**

Neil Hunter / Michelle Boxall  
Tel: +44(0) 20 8943 4685  
[neil.hunter@imageboxpr.co.uk](mailto:neil.hunter@imageboxpr.co.uk)  
[michelle.boxall@imageboxpr.co.uk](mailto:michelle.boxall@imageboxpr.co.uk)

### **NewCap – Investor relations**

Julien Perez / Pierre Laurent  
Tel: +33 (0)1 44 71 98 52  
[txcell@newcap.eu](mailto:txcell@newcap.eu)

## Forward-Looking Statements - TxCell

This press release contains certain forward-looking statements relating to the business of TxCell, which shall not be considered *per se* as historical facts, including TxCell's ability to develop, market, commercialize and achieve market acceptance for specific products, estimates for future performance and estimates regarding anticipated operating losses, future revenues, capital requirements, needs for additional financing. In addition, even if the actual results or development of TxCell are consistent with the forward-looking statements contained in this press release, those results or developments of TxCell may not be indicative of their in the future.

In some cases, you can identify forward-looking statements by words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets," or similar words. Although the management of TxCell believes that these forward-looking statements are reasonably made, they are based largely on the current expectations of TxCell as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of TxCell could be affected by, among other things, uncertainties involved in the development of the Company's products, which may not succeed, or in the delivery of TxCell's products marketing authorizations by the relevant regulatory authorities and, in general, any factor that could affect TxCell capacity to commercialize the products it develops, as well as, any other risk and uncertainties developed or identified in any public documents filed by TxCell with the AMF, included those listed in chapter 4 "Risk factors" of the 2015 *document de référence* approved by the AMF on May 24, 2016 under number R.16-048. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Notwithstanding the compliance with article 223-1 of the General Regulation of the AMF (the information disclosed must be "accurate, precise and fairly presented"), TxCell is providing the information in these materials as of this press release, and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.